Titre : | On the pharmaceuticalization of marijuana |
Titre traduit : | (La marijuana, produit pharmaceutique) |
Auteurs : | L. GRINSPOON |
Type de document : | Périodique |
Année de publication : | 2001 |
Format : | 377-383 |
Note générale : |
International Journal of Drug Policy, 2001, 12, (5-6), 377-383 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés CANNABIS ; USAGE THERAPEUTIQUE ; MEDICAMENTS ; FABRICATION ; INDUSTRIE DU MEDICAMENT |
Résumé : |
ENGLISH : Given the very limited toxicity of marijuana and the growing appreciation of its therapeutic value, it will undoubtedly find increasing application as a medicine in the coming years. But there is uncertainty about the forms in which it will be made available. Governments are hesitant to approve it because of concern about its use for nonmedical purposes and the difficulties of distributing as a medicine a substance that is already easily available. An alternative is the development of commercial cannabis pharmaceuticals that can be regulated and controlled. But pharmaceutical firms will be reluctant to invest the necessary money if they believe they cannot compete successfully with marijuana. Some of these products may have advantages over whole smoked or ingested marijuana, but most will not, and they will all be quite expensive. Ultimately, we can anticipate two medical distribution networks, a legal one for cannabinoid pharmaceuticals and an illegal one for street or homegrown marijuana. (Review's abstract) |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 9 |
Affiliation : |
Medical Sch., Univ. Harvard, 74 Fenwood Rd, Boston, MA 02115 Etats-Unis. United States. |
Numéro Toxibase : | 901162 |
Centre Emetteur : | 09 AMPT |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil